Oxygen shares soar following positive Levosimendan data

|By:, SA News Editor

Oxygen Biotherapeutics' (OXBT) Levosimendan product significantly improves post-operative kidney function in patients who have undergone surgery of the mitral valve in the heart, evidence from a study published in the Journal of Cardiothoracic & Vascular Anesthesia shows.

Oxygen Biotherapeutics expects to begin a Phase III trial of Levosimendan in Q3 for patients undergoing coronary artery by-pass and or mitral valve surgery.

Shares +22%. (PR)